Table 3 Treatments received by patients in the previous 24 months
NV-AMD treatmentPast 12 monthsPast 13–24 months
Better eyeWorse eyeBetter eyeWorse eye
Verteporfin, n (%)15 (20.0)4 (5.3)7 (9.3)6 (8.0)
Mean (SD) number of treatments*1.1 (0.3)2.0 (0.7)1.2 (0.4)1.5 (1.2)
Simultaneous verteporfin treatment in both eyes, n (%)2 (2.7)1 (1.3)
Mean (SD) number of treatments*1.0 (0.0)1.0 (n/a)
IVT corticosteroids4 (5.3)1 (1.3)1 (1.3)0 (0.0)
Mean (SD) number of treatments*1.3 (0.5)1.0 (n/a)1.0 (n/a)n/a
PDT with IVT corticosteroids0 (0.0)0 (0.0)0 (0.0)0 (0.0)
  • IVT, intravitreal; NV-AMD = neovascular age-related macular degeneration; PDT, photodynamic therapy; SD = standard deviation.

  • *Among subjects who received the treatment.